



A SYNTHETIC SHUTTLE FOR CYTOSOLIC DRUG DELIVERY IN CANCER THERAPY

10 SEPTEMBER 2026
AT 10:30 A.M.
ROOM A110 | POVO 1

Many of the most critical cancer drivers are located inside tumor cells, yet existing therapies often struggle to effectively and selectively deliver drugs into the cytosol in vivo. As a result, key intracellular cancer targets remain largely inaccessible. The iDEL platform enables direct cytosolic delivery of diverse therapeutic payloads, spanning small and large molecules, into patients' tumor cells through a unique, uptake mechanism upregulated in tumors. This mechanism has been observed to be highly active in multiple cancer types, supporting a broad potential application in solid tumors.



UNIVERSITÀ
DI TRENTO

Dipartimento di
Biologia Cellulare, Computazionale e Integrata - CIBIO



JÜRGEN MOLL

CHIEF SCIENTIFIC OFFICER
IDEL THERAPEUTICS GMBH
DORTMUND, GERMANY



DEPARTMENT OF CELLULAR, COMPUTATIONAL
AND INTEGRATIVE BIOLOGY - CIBIO
VIA SOMMARIVE, 9
38123 - POVO (TN)
COMUNICAZIONE.CIBIO@UNITN.IT